EICHORPublic-registry trials using Etrasimod that Eichor's radar has found — 1 trial. All data below is from public sources; Eichor is not affiliated with any sponsor.
Etrasimod appears in 1 registered trial Eichor's radar has found, sponsored by Pfizer, with a planned enrollment of 360. Registered timeline: 2024–2026. The registry holds 1,879 registered studies for Colitis, Ulcerative.
| Trial | Sponsor | Condition | Phase | Sites |
| A Study to Learn About the Effectiveness of Etrasimod in People With Ulcerative Colitis | Pfizer | Colitis, Ulcerative | — | 38 |
| Status | Recruiting · planned start 2024-05 |
| Primary completion | 2026-06 |
| Enrollment target | 360 participants |
| Design | 1 arms |
| Who it enrolls | All sexes · 18 Years and older — full criteria are on the study record |
| Locations | 38 listed in Canada, Germany, United Kingdom |
All fields verbatim from the ClinicalTrials.gov record for NCT06294925.
| First FDA approval | VELSIPITY — October 2023 (application NDA216956, currently held by PFIZER) |
| Also known as | VELSIPITY |
| Approved applications | 1 |
| Forms & routes | Tablet · Oral |
| Registry-wide use | 32 registered studies all-time · 9 currently recruiting |
Sources: FDA Drugs@FDA and ClinicalTrials.gov, public records. The application holder shown is the current holder, which may differ from the original developer.
The public registry holds 1,879 registered studies for Colitis, Ulcerative. Compounds appearing across the 200 most recently updated registry entries:
Eichor generates a preliminary site-risk snapshot — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
← Eichor home · All tracked trials · Colitis, Ulcerative studies · Weekly briefs
